Contribution to the inventory of French Healthcare companies with proven solutions that can be implemented in the management of the COVID-19 epidemic and patient management.
-> Atothis is the official distributor for France of the PrimerDesign diagnostic tests of the Novacyt group and of the CoVid-19 test for the detection of the SARS-COV2 coronavirus. This CoVid-19 test was designed to detect only the sequenced strains of 2019-nCoV that have been published and ignore the strains of other close coronaviruses such as SARS-CoV of the bat or MERS-CoV. It complies with the IVD directive 98/79 / EC and the ISO13485 standard.
In addition to its reliability and specificity, it has the advantage of being able to be shipped easily at room temperature and its lyophilized components have a shelf life of 18 months after its date of manufacture.
Website : www.ATOTHIS.fr
Contact : firstname.lastname@example.org . Benjamin Ingrat, sales department: email@example.com . Valéry Périnet, Management: firstname.lastname@example.org . Jacques Petrequin, technical and commercial service: +336 88 85 31 09, email@example.com
-> BioMérieux has announced the upcoming launch of 3 tests aimed at responding to the epidemic of COVID-19 including:
– ARGENE® SARS-COV-2 R-GENE® test – Available from the end of March (having to rapidly benefit from a CE marking and going to be the subject of an emergency use authorization request from the American FDA ). Can be performed by any type of laboratory using PCR techniques on most of the nucleic acid extraction and amplification platforms present on the market, it provides a result in 4 to 5 hours and makes it possible to test a large number of patients at a time.
– In parallel, development of a new fully automated test, using BIOFIRE® FILMARRAY® technology. With a result in about an hour, this test will be adapted to emergency situations of specific patient management.
– Finally, development of a new extended version of the BIOFIRE® FILMARRAY® RP2 respiratory panel which will integrate SARS-CoV-2 in addition to the 21 pathogens most frequently responsible for respiratory infections which it already allows to detect, in around 45 minutes.
These two BIOFIRE® tests will be submitted to the competent regulatory authorities in the 2nd and 3rd quarters of 2020 respectively.
In addition, bioMérieux markets EMAG®, a fully automated extraction platform for the purification of total nucleic acids from primary sample tubes. The extraction of genetic material is the first step in any molecular biology test and this platform allows: a single, standardized workflow for all samples and a generic extraction for DNA and RNA nucleic acids which can then be used with any identification technique. In the particular case of the fight against the coronavirus, this test is the first diagnostic response to the epidemic by allowing the very first tests proposed by learned societies and other centers to be performed.
–> Biosynex is specialized in the design and distribution of rapid diagnostic tests (RDT). Our company is the leader of the RDT French market with an annual turnover of 154M € in 2020.
Fast and easy to use, these RDTs are commercialized in France and in some 70 countries through various distribution channels (pharmacies, laboratories, hospitals…) By targeting the general public and health professionals, BIOSYNEX brings concrete and effective answers to public health issues at the heart of today’s preoccupations.
BIOSYNEX is also a key player in the fight against the coronavirus. Our company stood out in 2020 as one of the first laboratories in the world to develop the serological test that detects SARS-CoV-2 antibodies. We also manufacture and distribute COVID-19 PCR tests, antigen tests and self-tests for both healthcare professionals and the general public. BIOSYNEX has products listed on The Global Fund and is a supplier of WHO as well as several Foundations, NGOs and Governments.
Website : www.biosynex.com/en/
Contact : NORTH AREA – North America, Europe, North Asia – Mr. Christophe SAINT PIERRE firstname.lastname@example.org Tel.: (+33) 3 88 78 78 87
SOUTH AREA – Central and South America, Africa, Middle East, South-East Asia, Oceania – Mr. Marwan BOUANANI email@example.com Tel.: (+33) 3 88 77 57 28
-> BIOTEM is a French company specialized in immunotechnologies since 1980. In the context of the Covid-19 epidemic, our teams have been and remain mobilized with health actors and researchers.
Designed in collaboration with a multidisciplinary team (CNRS-ENS Paris-Saclay and Bichat AP-HP Hospital), BIOTEM offers a rapid test for the detection of the virus responsible for COVID-19. By combining 2 robust and proven technologies: RT-LAMP (reverse transcription loop-mediated isothermal amplification) with Lateral Flow Immunochromatography, the test offers the sensitivity and reliability with the ease and convenient result visualization of rapid strip tests (such as pregnancy tests).
Contact: Jonathan Mayali : firstname.lastname@example.org
->Cerba Healthcare has been able to carry out the COVID-19 diagnostic test in its biology laboratories since Monday March 9 with the support of the CNR of viruses responsible for respiratory infections of the Institut Pasteur (Paris) for the confirmation of positive cases . Together with its infectious biologists, Cerba has prepared notes and procedures that allow samples to be taken and samples to be delivered under optimal conditions.
-> DTF medical & Biospeedia provide healthcare professionals, companies and communities with a rapid nasopharyngeal antigen test ” Made in France “(Covid-19).
A partnership at the heart of the local French health ecosystem (Loire – France)
Designed and developed by Biospeedia, a spin-off of the Pasteur Institute based on the Health Innovations Campus of the city of Saint-Etienne ; produced at the Lyon site of the Delpharm group, a major player in pharmaceutical subcontracting; this test is distributed by the company DTF medical, a specialist in the distribution of medical devices.
A fast and reliable diagnostic test :
Beyond the similarity with PCR tests, antigenic tests for the detection of SARS-CoV-2 (Covid-19) are less expensive and faster, offering a result in less than 15 minutes. They are intended for use by professionals as a screening test and as an aid in the early diagnosis of active infection with SARS-CoV-2. Convenient to use, they do not require additional equipment and can be performed in general medicine. This test is officially listed by the French Ministry of Health.
A partnership which allows the French healthcare system to have a nasopharyngeal antigen test “made in France”, in support of the government actions to fight Covid-19 “Test – Alert – Protect”.
-> E3Cortex, is a French company located in the Hauts de France region (Northern France), specialized in manufacturing approved packaging for transfer of dangerous goods.
As such, E3 Cortex designs, develops and offers its customers ‘’Made in France’’ ready-to-use kits, to transport infectious substances, in strict compliance with applicable international regulations (P650 ADR and 650 IATA). These kits allow shipments of infectious and potentially infectious samples, for COVID-19 screening (Class 6.2, CATEGORY B, UN 3373).
For most practical purposes, note that E3 Cortex also designs and produces approved packaging (Class 6.2, CATEGORY A, UN2814 & UN2900), used for shipments of infectious substances that may cause permanent disability or deadly disease, for humans or animals, according to the definition of the applicable regulations (ex: EBOLA virus).
E3 Cortex offers a full range of products, tailored to everyone’s needs depending on their shipment conditions :
- Diagnobag, leakproof secondary packaging, standing the 95 kpA differential pressure tests
- Diagnobox, tertiary packaging, for shipments at ambient temperature (also available for shipments at controlled temperature)
- Biotainer (secondary container)
- Cryopack (Isothermal packaging)
E3 Cortex which is the only company producing this type of equipment in France, has been sollicited a great deal since the beginning of the pandemic, our teams showed total commitment to serve testing laboratories and hospitals in order to provide them with the necessary materials to shipp their screening tests.
->Eurobio Scientific offers its range of tests
-EurobioPlex SARS-CoV-2 Multiplex PCR in Real Time (Eurobio Scientific, France): kit of RT-PCR Multiplex, for the detection of the N gene and two fragments of the RdRp gene. Results in less than 1h30.
-Seegene (RT-PCR kit), AllPlex nCov assay (Seegene, South Korea): Seegene: Real-time Multiplex RT-PCR kit for E, N and RdRp gene detection. Results 1h30 approx.
-Maglumi 2019 nCov IgG and IgM (SNIBE, China): kit for quantitative detection of chemiluminescence type G or M antibodies, adaptable to all automata of the Maglumi range
-WANTAI SARS-CoV-2 Ab ELISA (Wantai, China): kit to detect total antibodies from plasma or serum samples. Results in 1h15.
-WANTAI SARS-CoV-2 IgM ELISA (Wantai, China): Type M immunoglobulin detection kit from plasma or serum samples. Results in 1h15.
-WANTAI SARS-CoV-2 Ab TDR (Wantai, China): total antibody detection kit from total blood, plasma or serum samples. Results in 15 minutes.
iLsa Diagnostic, for the conservation of human samples at -80 ° C as part of epidemiological studies related to COVID-19, makes available its R&D department to adapt its NEO® Sample Management aliquot robot to the vials and collection tubes COVID-19 samples. iLsa Diagnostic thus contributes to guaranteeing total security in the preservation and storage of samples and absolute traceability with all patient data and freezer management. iLsa Diagnostic is the designer and manufactures storage instruments and microplates in its factories in France.
Santé en entreprise (SEE) already uses a solution in Ivory Coast (connected teleconsultation case) which allows for multi-disease screening (HIV, viral hepatitis, diabetes, hypertension). With a group of partners (AlloDocteurs, TC4A, SD Biosensor, Orange …), SEE is implementing the “COVID-19 Mobile Lab”, a suitcase for detecting COVID-19, making people aware of barrier gestures and enabling them detect symptoms from their mobile phone, quickly train local teams of health professionals in diagnosis, equip them with teleconsultation bags for home screening, refer suspected cases to confirmation if necessary (PCR lab test).
LABELIANS designs, manufactures and retails a comprehensive offer of consumables, equipment, devices for the laboratories, aimed at meeting any demand towards collection, sampling, analysis, and conservation processes.( blood, urinary, fecal, joints and bones samples …). Our offer outstanding quality guarantees samples analysis reliability and repeatability for our customers not mentioning comfort and safety brought to patients and biologists.
To face pandemic, we have simply activated the strong connections built with our manufacturing partners for 50 years to consolidate a robust supply chain of labs devices that our customers need to go successfully and smoothly through diagnosis and vaccination processes around the world.
-> Soladis is a service company specializing in the analysis and enhancement of health data. In order to support the actors of Health in the urgent steps in connection with the COVID-19: pharmaceutical laboratories, biotechs, medtech, DTx… Soladis provides its bioinformatics, biostatistics and data sciences teams for the analysis of health data in link with COVID-19 allowing a better understanding of the disease and the effectiveness of associated treatments (preclinical, clinical, epidemiological data, etc.), allowing its better diagnosis, prognosis, or classification of patients at risk for personalized and personalized approaches. ’emergency (construction of algorithms).
-> TRONICO specializes in the design and manufacture of complex electronic products for demanding markets to third parties or its own trademarks. As part of the pandemic, TRONICO supported its sister company SkillCell in the development and sale of the EasyCOV salivary test solution. This integrated solution (test + implementation device + application) is approved and reimbursed in France and is used both domestically and abroad.
TRONICO markets this solution under the trademark TAME-CARE.
The EasyCOV solution has 5 advantages: performance equal to the best PCR tests (sensitivity 86%, specificity 99%), speed of implementation (40 min), comfort for the user (salivary sampling), mobile implementation (relocation on site) and robustness in the face of virus variants. It also lends itself very well to field use and in the management of the flow of people to be tested.
EasyCOV is part of the strategy of the government and local governments (regions, department) to mass test, as close as possible to the field.